Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
89Bio Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action requires a prosecution strategy that addresses the requirements of the assigned examiner. The concentration in Biotechnology & Pharmaceuticals defines the technical scope of the current applications at the patent office. Practitioners should ensure that the response to this pending matter is aligned with the company's intellectual property goals.
The prosecution involves 1 distinct examiner and 1 distinct art unit. The busiest examiner, CHO, DAVID H, is responsible for 1 pending office action. Because CHO, DAVID H is the 1 distinct examiner involved, the prosecution results depend on the interactions with this individual. The presence of 1 distinct art unit indicates that the technical subject matter is located within a specialized group. This concentration allows for an approach tailored to the examination process.
Practitioners should review the past office actions associated with CHO, DAVID H to prepare for the 1 pending office action. This engagement within the Biotechnology & Pharmaceuticals sector allows for a strategy tailored to the 1 distinct examiner. By focusing on the 1 distinct art unit, the company can navigate the legal interpretations favored by that department. The outcome of this application will be an indicator of the company's success in this field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18740787 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | CHO, DAVID H | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18740787 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | CHO, DAVID H | 1693 | §112 | Non-Final OA | — | Pending | Jun 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial89Bio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David H Cho has the most, with 1 of 89Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
